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Abstract
Background: Her2/neu is an oncogene that plays an important role in the pathogenesis of many cancer types. In
bladder carcinoma (BC), the clinical significance of Her2/neu status remains under-investigated and poorly linked to
the patients’ clinic-pathological features and survival status. Thus, the current study was conducted to assess Her2/
neu status in a cohort of patients’ in Saudi Arabia, and to explore its prognostic value in BC.
Methods: A total of 160 consent patients of transitional cell carcinoma (TCC) of bladder were arranged on a tissue
microarray (TMA) and stained by immunohistochemistry (IHC) and bright-field dual in situ hybridization (BDISH)
methods. The intensity of Her2/neu protein receptor immunostaining was evaluated, correlated to Her2/neu gene
amplification status in TCC and assessed for potential clinical value by correlation measures.
Results: IHC data demonstrated that Her2/neu protein is expressed in 60 % (2+ and 3+) of our TCC patient’s cohort
from Saudi Arabia. Her2/neu gene amplification is detected in 25 % by BDISH. There was a strong association
between Her2/neu protein levels and lymph node invasion (p = 0.04), tumor stage (p = 0.002), vascular invasion and
borderline significance with distant metastasis (p = 0.07). Amplification of Her2/neu gene was associated with tumor
grade (p = 0.03) and poor disease-specific survival (p = 0.02), in that, patients with non-amplified Her2/neu gene live
longer. Interestingly, there was a reasonable concordance rate (71 %) between IHC and BDISH data in the analyzed
cohort.
Conclusion: The study showed that 25 % of our patients’ cohort has Her2/neu over-expression. This Her2/neu
(over-expression/amplification) status was concordant using either IHC or BDISH and significantly associated with
disease aggressiveness and poor outcome. These findings suggested a potential impact of anti-Her2 targeted
therapy in the treatment of bladder cancer with amplified/overexpressed HER2 that needs further investigation.
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Background
Bladder cancer (BC) is a devastating disease and a
leading cause of death worldwide [1]. According to a re-
cently published data, BC is the sixth most common ma-
lignancy with an estimated 74,000 new cases and more
than 15,000 deaths of bladder cancer in the United
States on 2015 [2]. Despite important advances in cancer
treatment, the disease continues to pose a big challenge
to clinicians due to high recurrence rates, as 50–70 % of
new cancer cases recur within 5 years, and a great likeli-
hood to progress to an aggressive, muscle invasive and
metastatic forms [3, 4].
The management of BC relies enormously on the pa-
tients’ clinico-pathological parameters, such as TNM sta-
ging andgrading of the tumor, as indicators of good/poor
prognosis. However, these parameters are not sufficient
to predict patients’ outcome and worse yet, produce
large discrepancies within the same grade/stage. This is
mainly related to heterogeneity of bladder cancer cells
[5]. Intensive efforts are being made to develop novel
molecular tools in order to assist in the detection of the
disease at an early stage, enhance stratification of high
risk patients and improve clinical management [6, 7]. Al-
though initially promising, most of these tools have not
been sufficiently sensitive or specific which necessitate
the identification of additional robust biomarkers that
would more accurately predict for patient’s prognosis
and improve therefore BC surveillance in clinical setting.
The human epidermal growth factor receptor-2 (Her2/
neu) is a transmembrane glycoprotein, member of the
EGF family of tyrosine kinase receptors encoded by the
Her2/neu proto-oncogene [8]. In normal circumstances,
cells have low Her2 membrane protein content involved
in proliferation, differentiation, angiogenesis, and inva-
sion [9] but it increases dramatically in cancer cells. It
has been reported that Her2/neu protein is over-
expressed in several malignancies especially in gastric
(20 %) and breast cancers (up to 30 %) [10–12]. It is well
documented that Her2/neu over-expression is associated
with poor prognostic in breast cancer. Also, data emer-
ging from clinical trials revealed that the addition of the
monoclonal antibody against Her2/neu protein (trastu-
zumab) to chemotherapy enhanced the overall patients’
survival [13, 14].
A recent analysis of Her2/neu expression status in a
large cohort of patients across divers malignancies re-
vealed that bladder cancer exhibited a significant Her2/
neu protein over-expression (3+) assessed by immuno-
histochemistry (IHC) in more than 12 % of patients [15].
In an independent study using 111 BC samples, Bell-
munt et al. demonstrated that Her2/neu over-expression
was observed in 22 % of the analyzed cohort [16], and
could reached in some cases a record ratio of 74 %, as
reported elsewhere [17]. This is an interesting finding
that indicates that a large proportion of BC patients
could benefit from targeted anti- Her2/neu therapies.
Moreover, a number of phase II/III clinical trials are cur-
rently underway to assess the beneficial effect of anti-
Her2/neu and other therapies in urological cancer [18].
The aim of the present study is to determine the status
of Her2/neu in bladder cancer using two independent
methods IHC and BDISH. The level of concordance be-
tween the two methods will be evaluated. Correlation
between Her2/neu over-expression or gene amplification
with patients’ clinico-pathological parameters and the
significance of Her2/neu as a prognostic biomarker in
bladder cancer will be investigated.
Methods
Patients
The present series consists of 160 formalin-fixed and
paraffin-embedded (FFPE) tissue samples of primary tran-
sitional cell carcinoma of bladder cancer retrieved from
consent patients’ materials in the archives of the Pathology
Department, King Abdulaziz University Hospital (KAUH)
(Ethical Approval of KAUH IRB # 149-14). Patients were
diagnosed and treated mainly at the Departments of Path-
ology & Urology, King Abdulaziz University Hospital
(KAUH) and King Faisal Specialist Hospital and Research
Center (KFSHR), between 1996 and 2012. Only specimens
containing more than 80 % tumor cells were used for
analysis. The histo-pathological features of the carcinoma
specimens were classified according to the TNM classifi-
cation system. All clinical and pathological data of the
patients were collected from the patients’ medical records.
The key clinico-pathological data of the patients are
shown in Table 1.
Tissue microarray
Based on tissue microarray technique (TMA) as previ-
ously described [19], we successfully transferred approxi-
mately 160 blocks of bladder cancer to construct TMA
slides for evaluating the expression pattern of Her2/neu
status. Moreover, we also validated the TMA technique
in an integrative and comprehensive approach with IHC
for protein profiling of Her2/neu protein and BDISH for
Her2/neu gene profiling in bladder cancer samples. The
TMA technique seems to us as a feasible, useful and
multipurpose platform.
Immunohistochemistry (IHC)
Overexpression of Her2/neu protein was detected auto-
matically by IHC. The FDA-approved Her2/neu IHC
assay using PATHWAY Her2/neu rabbit monoclonal
antibody (clone 4B5; Ventana) was performed with
iView DAB Detection Kit (Ventana) on a BenchMark
XT automated staining system (Ventana). A protocol
was established so that the entire assay procedure
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consisting of deparaffinization with EZ Prep (Ventana)
at 75 °C, heat pretreatment in Cell Conditioning 1 (CC1;
Ventana) using “conditioner CC1 8 min,Mild CC1
30 min” for antigen retrieval at 100 °C, and then incuba-
tion with the anti- Her2/neu primary antibody for
16 min at 37 °C. The slides were counterstained with
Hematoxylin II (Ventana) for 4 min and Bluing Reagent
(Ventana) for 4 min. At the completion of the run, the
slides were removed from the automated slide stainer.
Following the staining step, the slides having residual
buffer and liquid coverslip solution on them were rinsed
first with a mild detergent followed by water until
complete removal of the soap. The slides were then
immersed into successive alcohol buffer at different con-
centrations (70 %, 95 %, 100 %) for 3 min to each. Then
one drop of Tissue-Tek glas mounting medium was ap-
plied onto a slide and covered with the glass coverslip.
Bright Field Double In Situ Hybridization (BDISH)
Her2/neu and Chromosome 17 probes were detected
using two colors chromogenic in situ hybridization
(ISH) in formalin-fixed, paraffin-embedded human
bladder cancer tissue specimens following staining on
VENTANA BenchMark XT automated slide stainer, by
light microscopy. The INFORM Her2/neu Dual ISH
DNA Probe Cocktail contains a Her2/neu probe (labeled
with the hapten dinitrophenyl or DNP) and a Chromo-
some 17 centromere probe (labeled with the hapten
digoxigenin or DIG) formulated with human placental
blocking DNA in a formamide-based buffer. The probes
were designed to detect amplification of the Her2/neu
gene in solid tumors. A protocol was established so that
the entire assay procedure consisting of baking for
30 min, deparaffinization with EZ Prep (Ventana) at 75 °C,
cell conditioning 2 (CC2; Ventana) using “Mild CC2 cycle
8 min, standard CC2 cycle 12 min, extended cycle 8 min”
followed by protease digestion with ISH protease 3 (ven-
tana) for 16 min at 37 °C. The genomic DNA in tissue sec-
tions and the nick-translated HER2 and CEN17 probes
were denatured by heat treatment for 20 min at 80 °C
followed by a hybridization step for 6 h at 44 °C. After
that, 3 stringency wash steps were performed at 72 °C with
2× SCC (Ventana). For HER2 gene detection, the slides
were incubated with a rabbit anti-DNP antibody for
20 min and then with HRP-conjugated anti-rabbit anti-
body for 16 min at 37 °C. The Her2/neu BDISH signal was
detected as metallic silver deposits with silver acetate,
hydroquinone, and hydrogen peroxide for 4 min at 37 °C.
For CEN17 detection, the slides were incubated with a
mouse anti-DIG antibody for 20 min and then with an
alkaline phosphatase (AP)-conjugated anti-mouse anti-
body for 24 min at 37 °C. The CEN17 BISH signal was
developed as red dot staining with fast red and naphthol
phosphate for 8 min. Finally, the slides were counter-
stained with Hematoxylin II for 8 min and with Bluing Re-
agent for 4 min. At the completion of the run, stained
slides having residual buffer and liquid coverslip solution
were rinsed in a mild detergent to remove the coverslip
solution, then rinsed with water only until soap was com-
pletely removed and finally dried at 45 °C for 15 min.
Slides were thereafter transferred into xylene bath for ap-
proximately 30 s then coverslips were applied by the
Tissue-Tek Film Cover slipper.
Scoring system of Her2 gene/protein amplification/
expression status
In order to assess both Her2/neu protein expression
pattern and corresponding gene amplification status in
bladder cancer, we have used the same scoring system
that has already been implemented for breast cancer
following the current ASCO/CAP guidelines [20]. The
scoring method for Her2 protein expression is based on
Table 1 Clinico-pathological characteristics of 160 patients of
transitional cell carcinoma of urinary bladder
Clinico-pathological features Patients number (%)
Gender
Male 133 (83 %)
Female 27 (17 %)
Age group (years)
≤60 70 (44 %)
>60 89 (56 %)
Lymph node involvement
Yes 18 (17 %)
No 86 (83 %)
Distant metastasis
Yes 17 (17 %)
No 83 (83 %)
Tumor Stage
I/II 100 (76 %)
III/IV 32 (24 %)
Tumor grade
Low grade 68 (44 %)
High grade 85 (56 %)
Vascular invasion
Yes 18 (17 %)
No 86 (83 %)
Recurrence
Yes 39 (26 %)
No 113 (74 %)
Status and end point
Alive 107 (68 %)
Died 50 (32 %)
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the cell membrane staining pattern. Her2/neu testing re-
sults by IHC fall into 3 categories: positive, equivocal,
and negative. Each of these results triggers different pa-
tient management. Cancer samples with equivocal IHC
were validated using BDISH to assess the HER2 gene
amplification status. The interpretation for Her2/neu
BDISH testing (Her2/neu/Chr17 ratio) is according to
(ASCO/CAP) scoring systems. BDISH staining results in
visualization via light microscopy in which Her2/neu ap-
pears as discrete black signals (SISH) and Chr17 as red
signals (Red ISH) in nuclei of cells. The Scoring
Algorithm for the Her2/neu Dual ISH DNA Probe
Cocktail is as following; non-amplified (Her2/neu/CEP17
ratio <1.8), equivocal (HER2/CEP17 ratio 1.8–2.2), and
amplified (Her2/neu /CEP17 ratio >2.2). However, ac-
cording to new regulation of ASCO/CAP guidelines for
ISH technique if the result is equivocal (Her2/neu/
CEP17 ratio is 1.8–2.2), you have to count extra 20 cells
for both Her2/neu and CEP17 and calculate the ratio
once again. If the ratio is below <2, non-amplified; and if
ratio is above >2, it is amplified.
Control samples
For quality control purposes, we used Her2/neu Dual
ISH 3-in-1 Xenograft of breast cancer slides provided by
the company (Roche Diagnostics GmbH, Mannheim,
Germany) representing the Her2/neu gene status in its 3
different categories; amplified (+3), equivocal (+2) and
non-amplified (0, +1), respectively. We stained these
xenograft tumor slides throughout the same run for
staining bladder cancer samples in both IHC and BDISH
experiments.
Statistical analysis
Statistical analyses were performed using the SPSS® (IMB
NY, USA) software packages (PASW Statistics for Win-
dows, version 19). Frequency tables were analyzed using
the Chi-square test, with likelihood ratio (LR) or Fischer’s
exact test to assess the significance of the correlation be-
tween the categorical variables. Odds Ratios (OR) and their
95 % Confidence Intervals (95 % CI) were calculated where
appropriate, using the exact method. Univariate survival
analysis for the outcome measure (DSS, DFS) was based
on Kaplan-Meier method, with log-rank (Mantel-Cox)
comparison test. In all tests, the values p < 0.05 were
considered as statistically significant.
Results
Expression patterns of Her2/neu protein profiling &
amplification status of Her2/neu gene in transitional cell
carcinoma of urinary bladder
The staining patterns and prevalence rate of Her2/neu pro-
tein profile and amplification status of Her2/neu gene re-
spectively, are illustrated in Fig. 1. The expression of Her2/
neu protein is mainly membranous. The frequencies of ex-
pression patterns of Her2/neu protein receptors in 160 of
bladder cancer samples evaluated by IHC technique were:
no expression (negative, 15 %), weak expression (+1, 25 %),
moderate expression (+2, 36 %) and strong expression pat-
terns (+3, 24 %), respectively (Fig. 2. A1-3), while the corre-
sponding frequencies of amplification status of Her2/neu
gene evaluated by BDISH technique were: non-amplified
Her2/neu gene status (75 %) and amplified Her2/neu gene
status (25 %), respectively (Fig. 2. B1-3).
Concordance rate between IHC and BDISH for evaluating
Her2/neu protein/gene status in transitional cell
carcinoma of urinary Bladder
Data showed that the two techniques have a reasonable
concordance rate in evaluating the Her2/neu status in blad-
der cancer (Table 2). The concordance rate was estimated
in 156 samples. Interestingly, 27/38 (71 %) of bladder
cancer samples which, showed +3 over-expression patterns
of Her2/neu protein have amplification (> 2) of their corre-
sponding Her2/neu gene while only 29 % (11/38) of over-
expressed Her2/neu proteins showed non-amplified (< 2)
Her2/neu gene, respectively. Surprisingly, all cases of low
expression patterns of Her2/neu protein profile (0/+1) 60/
60 (100 %) showed non-amplification (< 2) of correspond-
ing Her2/neu gene, i.e. also that no sample 0/60 (0 %) of
low expression (0/+1) samples showed amplification (> 2)
of corresponding Her2/neu gene. While in cases of border-
line/equivocal (+2) expression pattern of Her2/neu protein,
attractively, just about 46/58 (79 %) of samples showed
non-amplification (< 2) of corresponding Her2/neu gene
and 12/58 (21 %) of samples showed amplified (> 2)
correspondent Her2/neu gene, respectively (p < 0.005).
Correlation of IHC Her2/neu protein expression and
BDISH Her2/neu gene status with clinico-pathological
features
Our data showed that both age and gender had no sig-
nificant relationship with the expression pattern of
Her2/neu protein (Table 3). However, the involvement
of lymph nodes was significantly associated with more
Her2/neu protein expression pattern (p < 0.04). Regard-
ing the stage of the tumor, there was a highly significant
correlation between expression patterns of Her2/neu
protein and stage of the disease. In fact, high stage tu-
mors expressed more Her2/neu protein receptors com-
pared to those of low stage (p < 0.002). Interestingly, the
same trend was also observed with vascular invasion sta-
tus where tumors with vascular invasion showed more
expressed Her2/neu protein pattern profile as compared
to tumors with no vascular invasion (p < 0.01). However,
a correlation of borderline significance was observed be-
tween tumors with distant metastasis as contrasted to
those with no metastasis (p < 0.07). Moreover, the study
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demonstrated that higher tumor grade was associated
with amplified Her2/neu gene status as compared to low
grade tumors (p < 0.03, data not shown).
Correlation of IHC Her2/neu protein expression and
BDISH Her2/neu gene status with survival outcome
The survival data were available for 155 patients. Kaplan–
Meier survival analysis showed that there was a significant
(p < 0.02, log rank) difference in DSS between patients
with non-amplified Her2/neu gene status tumors who liv-
ing significantly longer (longer DSS) as compared with
those with amplified Her2/neu gene status tumors (Fig. 3).
In other words, the study showed that at 60 months
(5 years) follow up time, about 80 % of patients with amp-
lified Her2/nue gene were died of disease as compared to
only 42 % of their counterparts with non-amplified Her2/
neu. By using the IHC score, the survival analysis showed
a trend/tendency of high recurrence rate of cancer pa-
tients with high Her2 protein expression pattern as com-
pared to patients who have cancer with low Her2 protein
expression pattern. However this correlation was not sta-
tistically significant (p < 0.1, log rank, data not shown).
Discussion
Bladder cancer is the ninth most common and a leading
cause of cancer death worldwide [1]. High recurrence
rate and heterogeneous features of urothelial bladder
cancers are the major hurdles that hamper a suitable
clinical management [21]. The latter depends enor-
mously on several clinico-pathological factors such as
tumor grade, stage and lymph node invasion [22]. Hence
there is an urgent need to develop new diagnostic and
therapeutic modalities to meet clinical needs for the
management of bladder cancer. Recent advances in can-
cer research have improved our understanding of the
biological features of the disease and unveil relevant bio-
markers that are currently used in cancer stratification,
screening, diagnosis and prognosis [23]. In the last dec-
ade, human epidermal growth factor receptor 2 (Her2/
neu) has emerged as a potential biomarker in many can-
cer types especially breast, colorectal and gastric cancers
[14, 24–26]. Over-expression of Her2/neu protein and
gene amplification is associated with increased tumor
growth and poor prognosis and targeted Her2/neu ther-
apy has proven to be promising in breast cancer
treatment [13]. However, the clinical relevance of Her2/
neu in bladder cancer remains ambiguous and under-
investigated. This fact has strongly urged us to analyze
the expression patterns of Her2/neu status using two in-
dependent experimental techniques to assess its prog-
nostic and/or predictive value in our cohort of bladder
cancer patients, therefore better clinical management
scenarios will be foreseen for them.
In the present study, we used a cohort of 160 consent
patients with TCC of bladder cancer along with their full
set of clinico-pathological data. IHC results showed that
that Her2/neu protein was expressed in 60 % of the ana-
lyzed samples. The percentage of the Her2/neu protein
over-expressed (3+) was observed in 24 % of patients.
Previous published reports revealed that over-expression
of Her2/neu protein is highly variable in bladder cancer
ranging from 9.2 to 71 % [27–29]. This variability could
be attributed to several factors such as sample size, de-
tection method used, scoring criteria and ethnic origin
[16]. However, the most important finding in the current
study was that expression of Her2/neu correlated
Fig. 1 Histograms showed the frequency of expression patterns of Her2/neu protein receptors in 160 of bladder cancer by IHC (a) with
corresponding amplification status of her2/neu gene of the same samples by using BDISH technique (b)
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significantly with tumor stage, vascular invasion, lymph
node invasion and distant metastasis. Our observation is
consistent with previous findings where Her2/neu status
correlated significantly with lymph node metastases
from urothelial bladder cancer compared to the primary
tumors [30, 31]. This observation indicates that Her2/
neu is a valuable biomarker and/or effector associated to
the metastatic potential of tumor cells and provide merit
to exploring targeted Her2/neu therapy in patients with
metastatic bladder cancer [16, 32].
Table 2 Concordance rate between IHC and BDISH techniques for evaluating Her2/neu protein/gene status in transitional cell
carcinoma of urinary bladder (p < 0.005)
Her2/neu gene status (BDISH)
Non-Amplified (≤2) Amplified (>2) Total
Her2/neu protein expression patterns (IHC) Weak Expression (0,1+) 60 (100 %) 0 (0 %) 60
Borderline/equivocal Expression (2+) 46 (79 %) 12 (21 %) 58
High Expression (3+) 11 (29 %) 27 (71 %) 38
Total 117 39 156
Fig. 2 Validation and concordance rate of both IHC (A1-3) and corresponding BDISH (B1-3) of TMA spots for Her2/neu protein expression and
Her2/neu gene amplification patterns, respectively. Figures (1a-1b) represented 1+ membranous expression patterns (negative) of Her2/neu
protein (1a) and Non-amplified Her2/neu gene status (1b). Figures (2a-2b) represented 2+ membranous expression patterns (borderline) of Her2/
neu protein (2a) and amplified Her2/neu gene status (2b). While, figures (3a-3b) represented 3+ membranous expression patterns (high) of Her2/
neu protein (3a) and corresponding amplified Her2/neu gene status (3b) in TCC of urinary bladder. Magnification is X40
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Interestingly, high correlation between Her2/neu gene
amplification and tumor grade was observed (p = 0.03). In-
creased amplification of Her2/neu was more common in
higher histological grades than lower ones in several can-
cers including breast, bladder and osteosarcoma [33–35].
Similar correlations between Her2/neu status with high-
grade and advanced stages (III/IV) were also reported in
bladder cancer supporting more aggressive and proliferative
diseases with these patients [36].
In an independent approach, we carried out BDISH to
investigate the status of Her2/neu gene in order to validate
our IHC 2+ group and assess the concordance between
the two techniques. Despite some discrepancies regarding
the level of concordance between IHC and FISH methods
[37–39], so often both techniques consolidate each other
and generate similar results [27, 40, 41]. Despite that IHC
is more cost-effective and recommended by some studies
[42], it has been reported that assessing Her2/neu gene
amplification using in situ hybridization technique is a
more reliable and accurate method to evaluate Her2/neu
status in breast cancer patients [36, 43]. Here we report
that Her2/neu is amplified in 25 % of the analyzed
cohort which is in line with IHC data. Although a
reasonable concordance rate for Her2/neu testing by
IHC and BDISH was achieved in our cohort, higher
concordance between these two platforms were also
previously reported in urothelial carcinoma [44]. This
rate is below the threshold mandated by the new
ASCO–CAP guidelines [45]. However, the use of the
emerging digital droplet PCR as a new promising
Table 3 Correlation between Her2/neu protein expression patterns and clinico-pathological features of transitional cell carcinoma of
urinary bladder
Features Number of cases (%) Her2/Neu protein expression patternsa (%) p value
(0,1+) (2+) (3+)
Gender 0.19
Male 133 (83 %) 49 (37 %) 51 (38 %) 33 (25 %)
Female 27 (17 %) 15 (55 %) 7 (26 %) 5 (19 %)
Age group (years) 0.92
≤60 70 (44 %) 27 (39 %) 26 (37 %) 17 (24 %)
>60 89 (56 %) 37 (42 %) 31 (35 %) 21 (24 %)
Lymph node involvement 0.04
Yes 18 (17 %) 9 (50 %) 2 (11 %) 7 (39 %)
No 86 (83 %) 33 (39 %) 35 (40 %) 18 (21 %)
Distant metastasis 0.07
Yes 17 (17 %) 9 (53 %) 2 (12 %) 6 (35 %)
No 83 (83 %) 31 (37 %) 34 (41 %) 18 (22 %)
Tumor Stage 0.002
I/II 100 (76 %) 37 (37 %) 43 (43 %) 20 (20 %)
III/IV 32 (24 %) 18 (56 %) 3 (10 %) 11 (34 %)
Tumor grade 0.62
Low grade 68 (44 %) 27 (40 %) 27 (40 %) 14 (20 %)
High grade 85 (56 %) 35 (41 %) 28 (33 %) 22 (26 %)
Vascular invasion 0.01
Yes 18 (17 %) 10 (55 %) 1 (6 %) 7 (39 %)
No 86 (83 %) 31 (36 %) 36 (42 %) 19 (22 %)
Recurrence 0.61
Yes 39 (26 %) 14 (36 %) 15 (38 %) 10 (26 %)
No 113 (74 %) 47 (42 %) 40 (35 %) 26 (23 %)
Status and end point 0.59
Alive 107 (68 %) 41 (38 %) 41 (38 %) 25 (24 %)
Died 50 (32 %) 22 (44 %) 15 (30 %) 13 (26 %)
a(0,1+) = no expression and weak, (2+) = borderline and (3+) = high Her2/neu protein expression patterns
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technology which may help improving the accuracy of
Her2/neu copy number variation and reinforce these
two FDA-approved approaches for better clinical
outcomes [46].
Kaplan Meier survival curve revealed that amplifica-
tion of Her2/neu gene is significantly associated with a
poor prognosis and shorter overall survival (Fig. 3).
However, patients with non-amplified Her2/neu gene
were associated with prolonged DSS suggesting Her2/
neu as an independent prognosticator of overall survival
in bladder cancer (p = 0.02). This association was previ-
ously examined in many cancer types [12, 36, 47, 48].
The enhancement of cancer cell proliferation, motility,
invasion and metastasis are possible factors that sup-
port such poor prognostic impact of Her2/neu on the
overall survival in bladder cancer patients [49–51].
Additionally, previous findings reported an interesting
impact of anti-Her2 targeted therapy (Trastuzumab)
in the treatment of bladder cancer with amplified/
overexpressed HER2. In fact, 70 % of bladder cancer
patients with amplified HER2 were shown to respond
completely or partially but safely to Trastuzumab
treatment [52, 53]. Additional studies using larger
patients’ cohorts and randomized trials are required
to validate these urothelial bladder cancer survival
outcomes results and to investigate further the anti-
HER2 targeted therapy in Her2/neu overexpression
patients in clinical trial setting.
Conclusion
Our results showed a reasonable concordance rate be-
tween IHC and BDISH supporting that both approaches
can be used to assess the Her2/neu status. The discrep-
ancies between both approaches are expected since they
are affected by the experimental context and the pre-
analytical conditions. The use of digital droplet PCR
could be a good alternative for validation of these two
FDA-approved approaches given its high accuracy, sensi-
tivity and cost-effectiveness.
We reported herein and for the first time in Saudi
Arabia that 24 % of our patients’ cohort have Her2/neu
over-expression. Although this Her2/neu (over-expres-
sion/ amplification) status reported herein requires further
validation using larger cohorts of patients, it was signifi-
cantly associated with disease aggressiveness and poor
outcome. Our results together with previous findings pro-
vide new insight into the role of Her2/neu in TCC patients
who might benefit from anti-Her2/neu targeted therapy in
clinical trial setting especially those with locally advanced
and metastatic Her2/neu amplified bladder cancer.
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